Sharon Jackson

3.1k total citations · 1 hit paper
31 papers, 820 citations indexed

About

Sharon Jackson is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Sharon Jackson has authored 31 papers receiving a total of 820 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 11 papers in Pathology and Forensic Medicine and 11 papers in Hematology. Recurrent topics in Sharon Jackson's work include Lymphoma Diagnosis and Treatment (10 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Multiple Myeloma Research and Treatments (5 papers). Sharon Jackson is often cited by papers focused on Lymphoma Diagnosis and Treatment (10 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Multiple Myeloma Research and Treatments (5 papers). Sharon Jackson collaborates with scholars based in New Zealand, United Kingdom and United States. Sharon Jackson's co-authors include Michael Gent, Susan Solymoss, Jim A. Julian, Alexander G.G. Turpie, Jeffrey S. Ginsberg, Clive Kearon, James D. Douketis, Paul Ockelford, Jack Hirsh and Samantha Beswick and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Sharon Jackson

26 papers receiving 800 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

2022 124 citations Constantine S. Tam, John N. Allan et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sharon Jackson New Zealand	12	358	220	205	155	152	31	820
Debra Sarasohn United States	19	317 0.9×	265 1.2×	115 0.6×	110 0.7×	116 0.8×	36	1.2k
Peter Wood Australia	14	723 2.0×	573 2.6×	394 1.9×	90 0.6×	66 0.4×	36	1.1k
Grant M. Spears United States	15	153 0.4×	135 0.6×	171 0.8×	73 0.5×	59 0.4×	53	829
C. Tom Kouroukis Canada	18	418 1.2×	460 2.1×	346 1.7×	62 0.4×	383 2.5×	49	1.2k
Steven Andrèsen United States	16	205 0.6×	347 1.6×	138 0.7×	68 0.4×	417 2.7×	48	915
Hamed Daw United States	18	179 0.5×	380 1.7×	62 0.3×	108 0.7×	114 0.8×	99	954
Kyoung Ha Kim South Korea	17	163 0.5×	325 1.5×	99 0.5×	78 0.5×	144 0.9×	72	932
Rebecca Germino United States	9	128 0.4×	168 0.8×	141 0.7×	25 0.2×	234 1.5×	22	1.2k
Brian Berry Canada	15	1.2k 3.4×	768 3.5×	411 2.0×	31 0.2×	99 0.7×	27	1.7k
Axel Matzdorff Germany	20	151 0.4×	230 1.0×	249 1.2×	247 1.6×	747 4.9×	76	1.3k

Countries citing papers authored by Sharon Jackson

Since Specialization

Citations

This map shows the geographic impact of Sharon Jackson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon Jackson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon Jackson more than expected).

Fields of papers citing papers by Sharon Jackson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharon Jackson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon Jackson. The network helps show where Sharon Jackson may publish in the future.

Co-authorship network of co-authors of Sharon Jackson

This figure shows the co-authorship network connecting the top 25 collaborators of Sharon Jackson. A scholar is included among the top collaborators of Sharon Jackson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharon Jackson. Sharon Jackson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rawstron, Andy C., David Cairns, Nichola Webster, et al.. (2025). Optimising MRD-guided treatment: UMRD4 as a half-way treatment timepoint for ibrutinib-venetoclax substantially delays MRD relapse after end of treatment in both IGHV-mutated and IGHV-unmutated CLL.. Blood. 146(Supplement 1). 794–794.

Dalal, Surita, Darren Newton, Nichola Webster, et al.. (2025). Acquired Bruton's tyrosine kinase mutations in patients treated on the ibrutinib and rituximab, ibrutinib alone, and ibrutinib and venetoclax arms of the national multi-centre Phase III FLAIR study in previously untreated CLL patients. Blood. 146(Supplement 1). 796–796.

Jackson, Graham, Charlotte Pawlyn, Faith E. Davies, et al.. (2024). MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation. Blood. 144(Supplement 1). 3375–3375.

Pawlyn, Charlotte, Faith E. Davies, Gordon Cook, et al.. (2024). Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients - Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial. Blood. 144(Supplement 1). 1987–1987.

Ruskova, Anna, Christin Coomarasamy, Leanne Berkahn, et al.. (2023). Diffuse large B‐cell lymphoma at risk of secondary CNS involvement: The inefficacy of intravenous high‐dose methotrexate CNS prophylaxis and the importance of baseline cerebrospinal fluid analysis. American Journal of Hematology. 98(7). 1070–1079. 5 indexed citations

Tam, Constantine S., John N. Allan, Tanya Siddiqi, et al.. (2022). Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 139(22). 3278–3289. 124 indexed citations breakdown →

Wierda, William G., Paul M. Barr, Tanya Siddiqi, et al.. (2022). Fixed-duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (tx) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Three-year follow-up from the FD cohort of the phase 2 CAPTIVATE study.. Journal of Clinical Oncology. 40(16_suppl). 7519–7519. 3 indexed citations

Vulliamy, Tom, Inderjeet Dokal, Jean Soulier, et al.. (2021). Multinational Study on the Clinical and Genetic Features of the ERCC6L2-Disease. Blood. 138(Supplement 1). 864–864. 1 indexed citations

Chan, Henry, et al.. (2020). Electronic FRAIL score may predict treatment outcomes in older adults with myeloma. Journal of Geriatric Oncology. 12(4). 515–520. 3 indexed citations

10.

Mateos, María‐Victoria, Tamás Masszi, Norbert Grząśko, et al.. (2017). Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. Haematologica. 102(10). 1767–1775. 39 indexed citations

11.

Chan, Henry, et al.. (2016). Obese non-Hodgkin lymphoma patients tolerate full uncapped doses of chemotherapy with no increase in toxicity, and a similar survival to that seen in nonobese patients. Leukemia & lymphoma. 57(11). 2584–2592. 7 indexed citations

12.

Mateos, María‐Victoria, Tamás Masszi, Norbert Grząśko, et al.. (2016). Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1.. Journal of Clinical Oncology. 34(15_suppl). 8039–8039. 4 indexed citations

13.

Collinson, Fiona, Rachel A. Craven, David A. Cairns, et al.. (2013). Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection. Clinical Cancer Research. 19(18). 5227–5239. 58 indexed citations

14.

Jackson, Sharon, et al.. (2013). Full Uncapped Doses Of Chemotherapy In Non-Hodgkin's Lymphoma Patients With a High Body Surface Area Are Well Tolerated With No Increase In Toxicity, and a Trend Towards Improved Survival In Obese Patients. Blood. 122(21). 4343–4343. 1 indexed citations

15.

Newton‐Bishop, Julia, Samantha Beswick, Juliette A. Randerson‐Moor, et al.. (2009). Serum 25-Hydroxyvitamin D ₃ Levels Are Associated With Breslow Thickness at Presentation and Survival From Melanoma. Journal of Clinical Oncology. 27(32). 5439–5444. 214 indexed citations

16.

Kearon, Clive, Jeffrey S. Ginsberg, Jim A. Julian, et al.. (2006). Comparison of Fixed-Dose Weight-Adjusted Unfractionated Heparin and Low-Molecular-Weight Heparin for Acute Treatment of Venous Thromboembolism. JAMA. 296(8). 935–935. 159 indexed citations

17.

Jackson, Sharon, Mark Harland, Faye Turner, et al.. (2005). No Evidence for BRAF as a Melanoma/Nevus Susceptibility Gene. Cancer Epidemiology Biomarkers & Prevention. 14(4). 913–918. 21 indexed citations

18.

Jackson, Sharon, et al.. (1998). "Tower vertebra": a new observation in sickle cell disease. Skeletal Radiology. 27(4). 195–198. 15 indexed citations

19.

Jackson, Sharon & P. M. Stell. (1991). Second radical neck dissection. Clinical Otolaryngology. 16(1). 52–58. 8 indexed citations

20.

Connors, Joseph M., Paul Klimo, Nicholas Voss, R.N. Fairey, & Sharon Jackson. (1988). Testicular lymphoma: improved outcome with early brief chemotherapy.. Journal of Clinical Oncology. 6(5). 776–781. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact